High-dose chemotherapy and autologous stem-cell transplantation for DLBCL in the rituximab era

Affiliations

Comment

Michael Pfreundschuh et al. Lancet Oncol. 2017 Aug.

. 2017 Aug;18(8):989-991.

doi: 10.1016/S1470-2045(17)30467-9. Epub 2017 Jul 26.

¹ Saarland University Medical School, Innere Medizin I, D-66421 Homburg, Saar, Germany. Electronic address: michael.pfreundschuh@uniklinikum-saarland.de.

No abstract available

Comment on

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U. Chiappella A, et al. Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28. Lancet Oncol. 2017. PMID: 28668386 Clinical Trial.